Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 8/20 | 0.45 |
| ▸ | MMP2 | P08253 | 8/20 | 0.45 |
| ▸ | MMP8 | P22894 | 8/20 | 0.45 |
| ▸ | MMP3 | P08254 | 7/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 4/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL715198 | 0.79 | DPP4 (0.51) | — | |
| SCHEMBL715199 | 0.79 | DPP4 (0.51) | — | |
| SCHEMBL24579326 | 0.69 | MMP1 (0.38) | MMP1MMP2MMP8MMP3MMP13 | |
| SCHEMBL17991713 | 0.69 | MMP1 (0.45) | MMP1MMP2MMP8MMP3CTSL | |
| SCHEMBL19578707 | 0.68 | MMP1 (0.61) | MMP1MMP2MMP8MMP3MMP13 | |
| SCHEMBL17943266 | 0.67 | MMP1 (0.51) | MMP1MMP2MMP8MMP3MMP13 | |
| SCHEMBL25659773 | 0.67 | MMP1 (0.40) | MMP1MMP2MMP8MMP3MMP13 | |
| SCHEMBL966430 | 0.66 | CHRNB2 (0.40) | MMP1MMP2MMP8MMP3KMT2A | |
| SCHEMBL20413341 | 0.66 | HTR1A (0.44) | MMP1MMP2MMP8MMP3MMP9 | |
| SCHEMBL27630933 | 0.66 | MMP1 (0.54) | MMP1MMP2MMP8MMP3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183280-B2 | FAP inhibitors | VANTIA LIMITED (GB) | 2012-05-22 | — | — | US | disclosed |
| US-20100081701-A1 | FAP inhibitors | VANTIA LIMITED (GB) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081701-A1 | FAP inhibitors | FAP, APC, SERPINB1 | MMP1 737/4885MMP2 214/4885MMP8 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.